CClinicalTrials.gg
Enrolling by invitationNCT06329180Updated Mar 25, 2024

Exercise in Mental Illness Questionnaire: French Validation

An observational study in Exercise, sponsored by KU Leuven. Enrolling by invitation at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by KU Leuven · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
42
Ages
18 Years and older
Sex
All
01

Study summary

The validation of the French version of the Exercise in Mental Illness Questionnaire - Health Practitioner Version (EMIQ-HP) is a prospective observational case-only study involving: (a) translation to French, (b) an expert consensus meeting with French speaking experts from Canada to reach a first version, (c) back translation to English, (d) evaluation of the back-translation by the original authors of the EMIQ-HP, (e) an expert consensus meeting with French speaking experts from Canada to reach a final version based on comments of the original authors, and (f) test-retest reliability study. Test-retest reliability will be analysed through two points of measurement with an interval of 7 days.

Read the detailed description

The aim of this study is to cross-culturally validate the French translation of the Exercise in Mental Illness Questionnaire - Health Practitioner version (EMIQ-HP) scale and investigate the test-retest reliability. We hypothesize that the French validated translation of the Exercise in Mental Illness Questionnaire - Health Practitioner version (EMIQ-HP) scale will show and excellent test - retest reliability. National and international experts from Belgium, Canada and Switzerland are requested to join the expert panel and requested to be available on 2 different occasions, i.e. following the first translation and following the feedback of the original authors on the back translation in order to reach consensus on the final version. For the test-retest part of this study, all health care providers of the Centre Hospitalier Psychiatrique Chêne aux Haies (i.e. nurses, psychologists, physiotherapists, somatic medical doctors, psychiatrists) will be invited to participate. Following written informed consent procedure, participants will complete the EMIQ-HP which will be completed a second time exactly one week following the first completion

02

Conditions studied

  • Exercise

Browse trials for

03

In context

Mental Disorders

2,107 studies on the registry are indexed under Mental Disorders; 416 are open to participants now.

This study's planned enrollment of 42 is below the median of 200 across 480 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

KU Leuven is the lead sponsor of 358 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

National and international experts from Belgium and Canada will be requested to join the expert panel and requested to be available on 2 different occasions, i.e. following the first translation and following the feedback of the original authors on the back translation in order to reach consensus on the final version. For the test-retest part of this study, all health care providers of the Centre Hospitalier Psychiatrique Chêne aux Haies (i.e. nurses, psychologists, physiotherapists, somatic medical doctors, psychiatrists) will be invited to participate. There are no specific exclusion criteria.

Eligibility criteria

National and international experts from Belgium and Canada will be requested to join the expert panel and requested to be available on 2 different occasions, i.e. following the first translation and following the feedback of the original authors on the back translation in order to reach consensus on the final version. For the test-retest part of this study, all health care providers of the Centre Hospitalier Psychiatrique Chêne aux Haies (i.e. nurses, psychologists, physiotherapists, somatic medical doctors, psychiatrists) will be invited to participate. There are no specific exclusion criteria.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
42 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Intra-class-correlation coefficients (ICC 3,1

    EMIQ items

    Time frame: 7 days test -retest

07

Study locations

1 site
  • Centre Hospitalier Psychiatrique Chêne aux Haies
    Mons, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06329180
Lead sponsor
KU Leuven
Responsible party
Davy Vancampfort (Professor, KU Leuven) — Principal investigator
First posted
Mar 25, 2024
Start date
Mar 19, 2024
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Mar 25, 2024

Study contacts

Davy Vancampfort, Phd
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion